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“How do we produce work that touches the heart? We don’t want to live a frivolous life, 
we don’t want to live a superficial life. We want to be serious with each other, with our 
friends, with our work. That doesn’t necessarily mean gloomy or grim, but seriousness 
has a kind of voluptuous aspect to it. It is something that we are deeply hungry for; to 
take ourselves seriously and to be able to enjoy the nourishment of seriousness, that 
gravity, that weight”. Leonard Cohen 
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Kort norsk sammendrag - Short Norwegian summary 
Spirometri og pulsoksymetri er i økende bruk i allmennpraksis. Spirometri brukes både i 
diagnostikk og oppfølging av lungesykdommer og enkelte legemidler krever utført spirometri 
før de berettiger refusjon på blå resept. Pulsoksymetri er en undersøkelsesmetode for 
analysering av oksygenmetning i arterielt blod (SpO2). Testen er godt egnet for bruk i 
fastlegepraksis fordi den er enkel og rask å utføre.  Lave verdier kan tyde på hjerte- og/eller 
lungesykdom. 
Avhandlingen er basert på tre studier av voksne pasienter/individer, den første er et 
kvalitetssikringsprosjekt av egen praksis (Lillestrømstudien), den andre fra 7 fastlegepraksiser 
lokalisert i nord og sør Norge (DIOLUP studien) og den tredje fra en befolkningsundersøkelse 
(Tromsø 6). I alle tre studiene ble det utført lungefunksjonstesting med spirometri og i de to 
siste studiene ble oksygenmetning målt med pulsoksymetri. Lav oksygenmetning ble definert 
som SpO2 ≤95 % i begge studier. 
I Lillestrømstudien undersøkte vi allmennlegenes diagnosekoding før og etter endring av 
refusjonsreglene for inhalasjonssteroider i 2007. Forhåndsgodkjent refusjon til 
inhalasjonssteroider forutsatte diagnosen astma. Legene endret diagnose koder slik at de 
passet bedre med behandlingen som var gitt, flere fikk diagnosen astma. Spirometri var nyttig 
til å identifisere overforbruk av inhalasjonssteroider og bør sammen med sykehistorie og 
klinisk undersøkelse brukes til å kvalitetssikre pasientens behandling av obstruktive 
lungesykdommer i allmennpraksis. 
I DIOLUP studien, basert på pasienter i en stabil fase av sin astma og/eller kronisk obstruktiv 
lungesykdom (KOLS), var lav SpO2 forbundet med redusert lungefunksjon (FEV1 % av 
forventet), diagnostisert koronar hjertesykdom og alder > 65 år. Dette tyder på at 
pulsoksymetri kan være nyttige hos denne pasientgruppen i allmennpraksis. Lave verdier bør 
medføre at fastlegen gjør en ekstra vurdering av om pasienten er for dårlig behandlet av sin 
lungesykdom og/eller har udiagnostisert hjertesykdom. 
I befolkningsundersøkelsen Tromsø 6 ble sammenhengen mellom lave pulsoksymetriverdier 
og ekkokardiografiske målinger av venstre ventrikkels fylning undersøkt. Lav 
oksygenmetning var en signifikant prediktor for redusert diastolisk fylning (et mål for 
diastolisk dysfunksjon). Hypertensjon og overvekt var også signifikante prediktorer for 
redusert diastolisk fylning. Diastolisk dysfunksjon bør inkluderes blant mulig forklaringer når 
redusert oksygenmetning blir påvist. 
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English summary 
Spirometry and pulse oximetry tests are in increasing use in general practice. Spirometry is 
used in both the diagnosis and monitoring of respiratory diseases and in Norway some drugs 
require spirometry to have been performed before a prescription is reimbursed. Pulse 
oximetry is a non-invasive method for measuring oxygen saturation (SpO2). The pulse 
oximeter is a particularly helpful tool in primary care because it is tolerable for the patient, 
easy to use, acceptable within the time constraints of a busy practice and inexpensive. 
Decreased pulse oximetry values may indicate heart and/or respiratory disease. 
The thesis is based on three studies of adult patients/participants. The first is a quality project 
at our own practice (Lillestrøm study), the second a cross-sectional study in seven GP 
practices located in north and south Norway (DIOLUP study) and the third a cross-sectional 
study based on the sixth (2007/2008) survey of the Tromsø Study. In all studies, pulmonary 
function testing with spirometry was performed; in Studies II and III, oxygen saturation was 
measured by pulse oximetry. Low oxygen saturation was defined as SpO2 £ 95%. 
In the Lillestrøm study, we described how GPs’ diagnoses changed after new conditions for 
reimbursement of costs for inhaled corticosteroids (ICS) were introduced in Norway in 2006. 
The principle was that costs for ICS should only be reimbursed with a diagnosis of asthma. 
GPs’ diagnostic practice changed to make the diagnoses fit better with the treatment given. A 
clinical audit including spirometry was found to be useful for identifying overuse of ICS. 
Spirometry is useful in general practice for the follow-up of patients with obstructive lung 
diseases to assure their quality of treatment. 
In the DIOLUP study, based on patients in a stable phase of asthma and/or chronic 
obstructive pulmonary disease (COPD), patients with moderately decreased oxygen saturation 
had an increased risk of severely reduced lung function (FEV1% predicted) and co-morbid 
coronary heart disease. This suggested that pulse oximetry may be useful in these patients in 
general practice and that patients with SpO2 values £ 95% should be given special attention 
and followed up more closely than patients with normal oxygen saturation. 
In the sixth Tromsø study, the relationship between low pulse oximetry values and 
echocardiographic indicators of left ventricular filling was examined. Low oxygen saturation 
was independently associated with abnormal mitral Doppler flow as a measure of diastolic 
dysfunction. Hypertension and obesity were also significant predictors of impaired left 
ventricular filling. Diastolic dysfunction should be considered as a possible explanation of 
low SpO2 values.  
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ATS – American Thoracic Society 
A-wave – peak velocity flow in late diastole 
BMI – body mass index 
BSA – body surface area  
CI – confidence interval 
COPD – chronic obstructive pulmonary disease 
CRP – C-reactive protein 
CHD – coronary heart disease 
CV – coefficient of variation 
CVD – cardio-vascular disease 
EDT – E-wave deceleration time 
EPR – electronic patient record 
ERS – European Respiratory Society 
EUTRO – the Tromsø Study database 
E-wave – peak velocity flow in early diastole 
FEV1 – forced expiratory volume in 1 second 
FVC – forced vital capacity 
GOLD – Global Initiative for Chronic Obstructive Lung Disease 
GP – general practitioner 
HF – heart failure 
HFpEF – heart failure with preserved ejection fraction  
Hunt Study – Nord-Trøndelag Health Study 
ICS – inhaled corticosteroids 
LA – left atrium 
LV – left ventricular 
LVEF – left ventricular ejection fraction 
LLN – lower limit of normal 
OECD – Organisation for Economic Co-operation and Development 
OR – odds ratio 
PaO2 – partial pressure of oxygen in arterial blood 
PaCO2 – partial pressure of carbon dioxide in arterial blood 
pH – value for expressing the concentration of H+ ions 
	 13	
QRS complex – a combination of the Q wave, R wave and S wave represents ventricular 
depolarization on an electrocardiogram 
SaO2 – arterial oxygen saturation measured by blood gas test 
SD – standard deviation 
SpO2 – arterial oxygen saturation measured by pulse oximetry 
SPSS – Statistical Package for the Social Sciences 
TDI – tissue Doppler imaging 




BMI: body mass index, weight divided by height squared (kg/m2). 
Dyspnoea: uncomfortable awareness of one’s efforts to breathe. 
Hypoxia: insufficient oxygen supply. 
Hypoxaemia: low arterial oxygen supply; abnormally low level of oxygen in the blood. 
Obesity: BMI ³ 30 kg/m2. 
Pulse oximeter: non-invasive device for estimating oxygen saturation. 
Pulse oximetry: procedure of using a pulse oximeter. 
SpO2: normal value 96–100%; low value: £ 95%. 
1. Introduction 
This PhD thesis deals with methods of diagnosis and assessment of common pulmonary and 
heart diseases, which are frequently seen in general practice. 
1.1 Chronic obstructive pulmonary disease (COPD) 
Tobacco smoking is the most important cause of COPD in high-income countries and is also a 
risk factor for heart failure (HF)(1, 2). Other irritants, including workplace exposure to fumes, 
chemical substances, and dust, can also cause COPD (3), although the evidence that air 
pollution can cause the development of COPD is not conclusive (4). Genetic factors and 
childhood infections also play a role in the development of COPD (5). The disease develops 
when inflammatory mechanisms in the lung are activated and lead to tissue damage (6). 
Insufficient repair of alveolar structures leads to emphysema and repair with scarring causes 
airflow limitation and chronic bronchitis (6). Typical symptoms of COPD are chronic 
productive cough, wheezing, symptoms provoked by exercise and dyspnoea (7). Both 
crackles and wheezes are common findings on auscultation of patients with stable COPD and 
increase in frequency during exacerbations (8). However, disagreement about the use of terms 
describing lung sounds in patients with lung diseases weakens the diagnostic value of 
auscultation (9). Increased wheezing, as experienced by the patient, is associated with a drop 
in lung function during asthma and COPD exacerbations (8). An absence of wheezing or 
chest tightness does not exclude a diagnosis of COPD (9, 10). 
1.2 Asthma 
Asthma is a chronic inflammatory airway disease characterized by bronchial hyper-
responsiveness and reversible airway obstruction (11). It is characterized by episodic and 
reversible attacks of wheezing, chest tightness, shortness of breath and coughing. COPD and 
asthma have clear differences, but some patients have a mixture of both diseases (12). A 
typical patient is an asthmatic smoker who develops an airway obstruction that is not fully 
reversible airway obstruction (12). 
1.3 Heart failure (HF) 
HF results from injury to the myocardium from a variety of causes (13). Ischaemic heart 
disease and hypertension are the main causes of HF. The typical patient in general practice is 
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an older woman with long-standing hypertension, often suffering from diastolic HF, while 
cardiologists see predominantly men in their 60s who have had a myocardial infarction and 
are suffering from systolic HF (14). The pathophysiology underlying diastolic HF is 
heterogeneous and the patients are often older and have concomitant cardio-vascular disease 
(CVD) and non-CVDs such as COPD, diabetes, obesity, chronic kidney disease and anaemia 
(15, 16). In Western industrialized countries, the mean systolic blood pressure and the 
mortality from ischaemic heart disease have decreased (17), but other conditions are 
increasingly associated with HF, such as diabetes, COPD, valvular diseases and the use of 
cardiotoxic drugs. HF does not have a simple objective definition: its diagnosis requires the 
presence of several clinical features and objective evidence of cardiac dysfunction (18). 
Typical symptoms are breathlessness, orthopnoea, nocturnal dyspnoea, reduced exercise 
tolerance, fatigue and ankle swelling (15). Symptoms of HF are often non-specific and may 
be difficult to identify and interpret in patients with COPD (15). In a primary health care 
study from Finland, auscultation of the lung was usually performed in patients with HF (19). 
The prevalence of HF in this Finnish study was higher than in many clinical studies 
suggesting the occurrence of false-positive HF diagnosis in primary health care (19). Lung 
auscultation is commonly used in clinical practice but has limited diagnostic value in HF (20, 
21). 
With increasing life expectancy, HF has become an increasing health problem in 
industrialized countries. In high-income countries, it is the most common diagnosis in patients 
aged 65 years or older who are admitted to hospital (22). Hospital admissions for congestive 
HF can be avoided if high-quality primary care is provided (23). In Norway, in 2010 the rate 
of hospital admissions for congestive HF was 1.6 per 1000 population, which is much lower 
than the Organisation of Economic Co-operation and Development (OECD) average of 2.4 
per 1000 (23). Access to primary care is generally good in Norway (23). 
Despite some progress, the prognosis of HF is worse than that of most cancers (22). Coronary 
heart disease (CHD) carries the highest relative risk among the risk factors for HF (24). 
Registry studies have revealed that HF with preserved ejection fraction (HFpEF) represents 
approximately half the acute presentations of HF and has similarly high mortality and re-
hospitalization rates as those for patients with HF and reduced EF (25). 
1.4 Coexistence of obstructive pulmonary diseases and heart failure 
HF, COPD, and asthma frequently coexist (26). COPD and HF share one common symptom, 
namely shortness of breath. In clinical practice, the diagnosis of COPD and HF is often based 
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on history, without spirometry and echocardiography, which are needed for reliable diagnosis 
(26). Pulmonary congestion may cause airway obstruction because of external obstruction of 
alveoli and bronchioles in patients with heart failure leading to a false diagnosis of COPD 
based on the spirometry criterion of a ratio of forced expiratory volume in 1 second (FEV1) to 
the total volume of air that the patient can forcibly exhale in one breath, forced vital capacity 
(FVC) (i.e., FEV1/FVC) < 0.7 (27, 28). Both intra- and extra-broncheolar (fluid) obstruction 
can cause a reduction in FEV1/FVC, but pulmonologists often consider only the first (28). 
Accordingly, the diagnosis of co-morbid COPD in HF should not be based on a single 
spirometry test in unrecompensated HF patients (27). This may be why the reported 
prevalence rates of COPD among HF patients range from 9 to 52% (18). COPD may be 
overdiagnosed in patients with HF; it is important to keep this in mind to avoid potentially 
harmful overtreatment with bronchodilators (27). Spirometry should be performed when 
patients are in a stable phase of their HF (28). 
The coexistence of COPD and HF increases the risk of death (26). In the general population, 
COPD is more prevalent than HF and unrecognized HF is common in older patients with 
stable COPD diagnosed by a general practitioner (GP) (29, 30). CVD and COPD are the first 
and the fourth leading causes of death from disease worldwide (31). In general practice in the 
United Kingdom, the consultation rates for COPD exceed those for ischaemic heart disease 
(32). Many people suffer from COPD for years, and die prematurely from it or its 
complications (33). In a single primary care practice, the main causes of death in COPD 
patients were CVD, COPD exacerbation and lung cancer (34). Most deaths in people with 
mild to moderate COPD are the result of CVD or lung cancer, but in patients with severe 
COPD, death because of this respiratory disease is common (35). In 2014, 30% of deaths in 
Norway were caused by CVD and 5% were caused by COPD, chronic bronchitis or 
emphysema (36). Lack of awareness and late detection of these conditions are issues, and it is 
essential to support and develop the primary health care services required for their early 
detection and management (37). Treatment of COPD is now aimed at reducing the impact of 
symptoms and the risk of future adverse health events, which requires individualized 
assessment of the disease (38). 
The relationship between COPD and CVD is clinically relevant because CVD is the most 
common co-morbidity and the leading cause of hospitalization in patients with mild to 
moderate COPD (39). Evidence suggests that patients with COPD should be screened for 
concomitant atherosclerosis and patients with CVD for concomitant airflow limitation (40). In 
the Lung Health Trial, in which 6,000 patients were followed over 14 years, impaired lung 
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function (assessed by FEV1) was an independent predictor of dying from a myocardial 
infarction (41). COPD, independent of cigarette smoking and aging, doubles the risk of CVD 
hospitalization and death (39). Even in patients with mild COPD, evaluation for occult CVD 
is warranted and aggressive treatment to reduce the burden of both lung disease and 
atherosclerosis is needed to mitigate the future risk of acute cardio-vascular events in patients 
with COPD (42). Exertional breathlessness, paroxysmal nocturnal dyspnoea and nocturnal 
cough are common in both HF and COPD (18). No qualitative features of dyspnoea are 
unique to HF (43). Clinical symptoms require careful interpretation, together with objective 
evidence of each disease (18). 
1.5 Pathophysiology of low oxygen saturation 
Ventilation/perfusion mismatch in COPD is caused by airflow limitation and emphysema: 
hypoxia leads to pulmonary vaso-constriction and right cardiac chamber enlargement (cor 
pulmonale) (44). Pulmonary arterial hypertension is secondary to COPD and the prevalence 
of right ventricular hypertrophy and right cardiac chamber enlargement is higher in patients 
with severe COPD than in those with mild to moderate COPD (45). COPD patients also have 
a high prevalence of left ventricular diastolic dysfunction (DD), which is associated with 
disease severity (44). One explanation for this association may be that cor pulmonale alters 
left ventricular geometry because of interventricular septum deviation towards the left 
ventricle and then delayed filling of the left ventricle (46). Another explanation for the 
relationship between airflow limitation and DD is inflammation (44). In COPD, inflammation 
is one of the systemic manifestations that can lead to the development of atherosclerotic 
plaque, which can cause myocardial ischaemia and lead to left ventricular DD (44). 
A patient’s history and a physical examination should guide the selection of the initial 
diagnostic tests such as electrocardiogram, chest radiograph, pulse oximetry, spirometry, 
complete blood count and a metabolic panel. If these are inconclusive, additional testing is 
indicated (47). 
1.6 Spirometry 
Spirometry is an indispensable tool in primary care for the diagnosis and monitoring of 
chronic airway disease (48). Spirometry measures the flow and volume of air entering and 






In the forced expiratory manoeuvre, a patient is asked to take the deepest breath possible, and 
then exhale into the spirometer (Figure 1) as hard and for as long as possible – for at least 6 
seconds. The flow–volume loop is obtained by plotting flow against volume during the forced 
expiratory manoeuvre. During the test, soft nose clips may be used to prevent air escaping 
through the nose and filter mouthpieces to prevent the spread of microorganisms. Spirometry 
is used to assess ventilatory function and differentiates between normality and disease causing 
obstructive, restrictive and mixed defects (Figure 2). The spirometry procedure is 
standardized and reference values (called predicted values) based on sex, age and height are 
available for populations of healthy never smokers. The most commonly used values are 
FEV1, FVC and the FEV1/FVC ratio. FEV1 is the maximum volume exhaled in the first 
second of a forced exhalation that follows a full inspiration. Both the configuration of the 
loops and the spirometry volumes are used to classify the pattern as normal (dotted line in 
Figure 2), obstructive (low ratio of FEV1/vital capacity in Figure 2 a and normal ratio of 
FEV1/vital capacity in Figure 2 b), restrictive (described in 1.6.2) (Figure 2 c) or mixed 




a), b) Obstructive pulmonary defects, c) restrictive defect and d) mixed defect. The normal 
pattern is shown by the dotted line (49). 
 
Reproduced with permission of the European Respiratory Society; Eur Respir J. November 
2005, 26:948–968; doi:10.1183/09031936.05.00035205 
 
According to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), spirometry indicates the presence of an abnormality if FEV1 < 80% of the predicted 
value, FVC < 80% of the predicted value and the FEV1/FVC ratio is < 0.7. 
1.6.1 Obstructive pattern 
In the obstructive pattern, there is a disproportionate reduction in FEV1 compared with FVC 
(FEV1/FVC < 0.7). FVC can be normal or reduced, usually to a lesser degree than FEV1. 
Spirometry is required to make the diagnosis of COPD; the presence of a post-bronchodilator 
FEV1/FVC < 0.7 confirms the presence of persistent airflow limitation (9). The fifth 
percentile lower limit of normal (LLN) for FEV1/FVC can be used instead of the fixed ratio 
of 0.7 because the fixed ratio overestimates airflow limitation in older people and under-
estimates it in young people (50, 51). Interestingly, the results from a population-based 
Canadian study in 2015 indicated that a low FEV1/FVC ratio by either the fixed ratio and/or 
LLN criterion coupled with a low FEV1 (< 80% of predicted) is the most clinically relevant 
diagnostic criterion for COPD (52). LLN criterion used alone may lead to misdiagnosis of 
COPD (52). 
1.6.2 Restrictive pattern 
The gold standard for detection of a restrictive lung pattern is body plethysmography, which 
can measure total lung capacity (TLC) (53). Low FVC is a screening criterion for a restrictive 
lung pattern because TLC cannot be measured with a spirometer. The restrictive pattern by 
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lung volume is characterized by a reduction in the FVC with a normal or increased 
FEV1/FVC ratio (FVC < 80% and FEV1/FVC ³ 0.7). 
1.7 Spirometry in primary care 
Spirometry has been shown to be both feasible and reliable in general practice (54, 55), but 
the variation in performance may indicate a potential for quality improvement (56). Good 
quality spirometric measurement is possible in any health care setting and spirometry is the 
most reproducible and objective measurement of airflow limitation (9). Despite this, under-
use of spirometry when diagnosing obstructive lung disease is common (57-60). A study from 
Greenland of patients aged 50 years or over taking medication for obstructive lung disease 
found that only one-third had had spirometry performed within two years (61). In a Danish 
study, patients receiving first-time prescriptions for medication targeting obstructive lung 
disease had higher odds of having spirometry performed if their general practice was a 
partnership practice (56), and increasing age of GPs was associated with decreasing 
spirometry testing (56). In contrast, in a Norwegian study, the age of the GPs was not 
associated with spirometry testing (62), although the odds for a patient to be tested with 
spirometry were six to nine times higher in the GP practice with the highest use of spirometry 
compared with the GP practice with the lowest use of spirometry (62). When spirometry is 
not performed, patients may experience an unnecessary delay in the diagnostic process. 
1.8 Arterial blood gas analysis 
The gold standard to estimate oxygen saturation is arterial blood gas analysis. Oxygen 
saturation (SaO2) measures the percentage of haemoglobin binding sites in the bloodstream 
that are occupied by oxygen (63). Arterial blood gas analysis measures the blood arterial 
oxygen tension (PaO2) and estimates SaO2, which is the arterial oxygen content carried by 
haemoglobin. In addition, arterial carbon dioxide tension (PaCO2), acidity (pH) and serum 
bicarbonate (HCO3–) concentration can be estimated. Changes in body temperature, PaCO2, 
2,3-diphosphoglycerate or pH alter oxygen binding to the haemoglobin and its release to the 
tissue. This may cause SaO2 measurements to be inaccurately calculated because of the 
relationship between PaO2 and SaO2 (the oxygen dissociation curve). In cases of 
hypoventilation, it is important to analyse arterial blood gas (pH, PaO2 and PaCO2), and not 
only perform pulse oximetry (SpO2) because the latter gives no information about arterial 
PaCO2 or acid–base status (64). A complete respiratory assessment includes both oxygenation 
(PaO2, SaO2 and SpO2) and ventilation (PaCO2, i.e., how well a patient can exhale CO2 
	 22	
produced by metabolic activities). Hypoventilation may cause hypoxaemia as shown by pulse 
oximetry, but this does not always indicate that it is appropriate to start treatment with oxygen 
supplementation. The treatment of hypoventilation is primarily directed at correcting the 
underlying disorder. For example, if respiratory depression occurs because of opioid 
overdose, the treatment is an opioid antagonist (naloxone). Treatment of hypoventilation is 
also aimed at assisting ventilation (mechanical-invasive or non-invasive). 
Arterial blood gas analysis should also be performed when dyshaemoglobin or carbon 
monoxide (CO) poisoning are suspected. Pulse oximetry (SpO2) is unreliable in these 
conditions. 
Hypoxaemia (insufficient oxygen in the blood) is a sign of a problem related to breathing or 
circulation. There must be enough oxygen in the air being breathed, the lungs must be able to 
inhale the oxygen-containing air and exhale CO2, and the bloodstream must be able to 
circulate blood to the lungs, take up the oxygen and carry it out to the body. Problems with 
some of these conditions, for example, high altitude, asthma/COPD or heart disease, might 
result in hypoxaemia. Other causes of hypoxaemia are chemical or gas poisoning, medications 
that reduce the effort of breathing, anaemia and/or conditions that destroy red blood cells. 
The symptoms of hypoxia usually consist of shortness of breath, rapid breathing, fast heart 
rate, wheezing, sweating and coughing. A blood-gas reference study performed at sea level 
found a mean SaO2 of 95.5%–96.9% (SD 0.4–1.4), depending on age (18 years or over) (65). 
Reference values for SaO2 in older people (³ 70 years) are sex-specific but age-independent: 
the mean SaO2 was found to be 95.3% (SD 1.4) for men and 94.8% (SD 1.7) for women (66). 
SpO2 values < 97% are rare in asymptomatic, awake adults (median age 38 years, 
interquartile range, 28–48) (67). 
An arterial blood gas analysis involves puncturing an artery, which may be painful; there is a 
small risk of bleeding, pseudo-aneurysm, infection or nerve injury. Arterial blood gas analysis 
is invasive, time-consuming and is seldom used in GP offices (68). 
1.9 Pulse oximetry 
Pulse oximetry is used to measure the peripheral oxygen saturation (SpO2), which can be used 
as an estimate of arterial oxygen saturation (SaO2). The pulse oximeter (Figure 3) is easy to 
use, acceptable within the time constraints of a busy practice and tolerable for the patients. 
Clinicians may consider pulse oximetry to be a vital sign. A decreased pulse oximetry value 






The technology makes it possible to distinguish between oxyhaemoglobin and 
deoxyhaemoglobin. It uses two different light-emitting diodes (LEDs), one emitting red light 
at approximately 660 nm and the other infrared light at approximately 940 nm (Figure 4). 
Because of its red colour, oxyhaemoglobin absorbs less red light than deoxyhaemoglobin. 
The light passing from the LED through the finger is measured by the photodetector 
positioned opposite to the LED. Each LED is illuminated at a programmed frequency. The 
software of the oximeter assumes that all the light reaching the photodetector has the 
wavelength of the illuminated LED. To differentiate between venous blood and arterial blood, 
calculation of the saturation is based on the difference between absorption through systole and 
diastole. During cardiac systole (denoted by the onset of the QRS complex), there is an 
increase in light absorption that is assumed to be created by the influx of arterial blood 
(Figure 5). The software determines the difference between absorption during diastole and 
systole at both wavelengths. Increased red-light absorbance is associated with increased 
deoxyhaemoglobin, i.e., lower SpO2 (Figure 5). The microprocessors are calibrated using 
reference tables for healthy people exposed to SaO2 values of 75–100%. 
The standard manufacturing claim for accuracy for pulse oximeters is ± 2–3% over the range 
of 70–100% SpO2 (69). In a study of pulse oximeters in use in hospitals in the U.K., 22% of 
those tested had inaccuracies in saturation estimation of < 4% in the range of 70–100% 
saturation (69). 
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In a study in children, pulse oximetry was found to be reliable for exclusion of hypoxaemia 
(70). Using SaO2 < 90% as the gold standard for hypoxaemia, its negative predictive value for 




Reproduced with permission PureSAT® Technology. 
 
Figure 5 
A schematic diagram of light absorbance by a pulse oximeter (71). 
Reproduced with permission from Respiratory Medicine, Vol. 107, Page 791. 
1.10 Pulse oximetry in primary care 
Data on the role of pulse oximeters in general practice are limited (68). The advantage of 
pulse oximetry lies in the fact that it is non-invasive and is not affected by inter-observer or 
intra-observer variability in clinicians. In primary care, pulse oximetry may be a helpful 
diagnostic test in assessing the severity of disease and in clinical decision management 
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(Table 1). An oxygen saturation (SpO2) £ 92% indicates hypoxaemia, but values between 
93% and 95% are lower than normal (10, 48, 68, 72). Examples of use in general practice are 
the management of acute exacerbations and when long-term oxygen therapy may be required 
in COPD patients, in grading the severity of an asthma attack, assessing the severity of cases 
of community-acquired pneumonia and in acute paediatric assessment for measurement of 
respiratory status (68). It is not clear whether pulse oximetry has a role in acute assessment of 
children in general practice (68), but according to the U.K.’s National Institute for Health and 
Care Excellence guideline (73), SpO2 £ 95% is an amber flag feature when assessing children 
with acute febrile illness. Under these conditions, the GP should consider pneumonia (73). 
Pulse oximetry is not a valid method for diagnosis of COPD (74). 
Recommendations from GOLD in 2015 (38) include: 
“Pulse oximetry can be used to evaluate a patient’s oxygen saturation and need for 
supplemental oxygen therapy. Pulse oximetry should be used to assess all stable patients with 
FEV1 less than 35% predicted or with clinical signs suggestive of respiratory failure or right 
heart failure. If peripheral saturation is less than 92%, arterial blood gases should be 
assessed (38)”. 
The British guideline for the management of asthma (2016) (75) recommends in-patient 
treatment of children with acute asthma and SpO2 < 92% after bronchodilator treatment. 
Norwegian national guidelines for COPD recommend pulse oximetry examination in general 
practice (76). The patient should be informed of their SpO2 value when they are in the stable 
phase of COPD, and should be referred to the pulmonary department at the hospital for 
arterial blood gas measurement if their SpO2 is < 92% (76). Pulse oximetry measurements 
should be performed for the monitoring of patients with severe COPD and in patients with 
dyspnoea (Modified Medical Research Council Dyspnoea Scale ³ 2) (76, 77). A change in 
SpO2 value to SpO2 < 90% during an exacerbation of COPD indicates a need for hospital 
admission (76). Oxygen supply should be used on flights over 1 hour by COPD patients with 
SpO2 < 92% at sea level (76). 
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Table 1 Decreased pulse oximetry value as a criterion for considering hospital referral 
 
Disease Situation Criterion for considering 
hospital referral 
COPD Exacerbation SpO2 < 90% (76, 78) 
COPD Screening for long-term 
oxygen requirement 
SpO2 < 92% (76, 79) 
Asthma Acute asthma attacks in 
children and adults 
SpO2 < 92% (75) 
Pneumonia Assessing severity  SpO2 < 94% (80)a 
Febrile illness in children 
(pneumonia) 
Assessing severity SpO2 £ 95% (73) 
aIn healthy individuals 
1.11 Echocardiography 
Transthoracic echocardiography is currently the most widely used diagnostic tool for 
evaluation of myocardial function and can assess pump function, anatomical changes, blood 
flow, valve function and wall movements of the heart. One disadvantage of echocardiography 
is that ultrasound waves cannot image through bone, tissue and air. Accordingly, it is difficult 
to examine the hearts of obese patients, patients with large breasts and those with 
emphysema. The ejection fraction (EF) expresses the volume of the left or right ventricular 
(LV or RV) chamber that is emptied during each contraction divided by the end diastolic 
volume. The normal value for LVEF is usually considered to be ³ 50% (15). Doppler 
echocardiography is a useful tool for assessment of LV diastolic function (81). The methods 
for classification of diastolic function, which have been validated against mortality as an end-
point, include pulsed-wave Doppler examination of mitral inflow, Doppler recordings of 
pulmonary venous flow and tissue Doppler imaging (TDI) of mitral annular movement (82). 
According to the recent Recommendations for the Evaluation of Left Ventricular Diastolic 
Function by Echocardiography of the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging, 2016 (83), the four recommended variables 
for identifying DD are mitral annular tissue Doppler velocity (e¢) (septal e¢ and lateral e¢), 
average ratio of mitral passive inflow (E) and tissue Doppler velocity (E/e¢), left atrial volume 
index, and peak tricuspid regurgitation velocity. LV diastolic function is considered to be 
normal if more than half of the available variables do not exceed the cut-off values for 
identifying abnormal function (83). This 2016 classification has not yet been validated against 
mortality or hospitalization for heart failure as end-points. 
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1.12 Pulse oximetry and cardio-vascular disease (CVD) in adults 
CVD contributes to heart failure, which affects pulmonary function and gas exchange (84), 
and thus leads to decreased SpO2. Decreased oxygen saturation measured by pulse oximetry 
has been found in association with acute heart failure (85). In patients admitted to hospital 
with acute myocardial infarction, pulse oximetry is useful in establishing the diagnosis and 
severity of heart failure (85); heart failure may be suspected when SpO2 is < 93% (85). In an 
adult cohort study from Norway, low SpO2 was significantly associated with death caused by 
heart failure (10). In the treatment algorithm for acute heart failure (86), pulse oximetry is one 
of the recommended tests, with a cut-off value for SpO2 of < 90% (86). 
1.13 Pulse oximetry in general practice: two patient stories 
In February 2014, one of my patients came to a consultation for follow-up of her diabetes; she 
also had severe COPD and CHD. During the dialogue, she spoke less than usual, only 
answering yes or no to my questions. I asked her about breathlessness, which she denied. I 
measured her SpO2, which was 90%. I told her that her oxygen saturation was lower than 
usual. She coughed several times before she answered that she had had increased purulent 
sputum in recent days and that she indeed had increased dyspnoea. She told me that she 
wondered if she would be able to leave the house on that day, but she did not want to worry 
me about this because I was so late and the consultation was ordered for diabetes control. The 
consultation ended with my treating her for a COPD exacerbation. 
In January 2018, I received an electronic communication from one of my patients, a woman 
aged 46 years with a diagnosis of asthma. “I need help from you because of severe trouble in 
breathing, especially at night, and a cough with sputum. My oxygen saturation was 90% last 
evening before I went to bed.” I gave her an instant response and asked her about pulse 
oximetry measurements at home. She explained that her two children, aged 8 and 12 years, 
had severe asthma, and had been referred to hospital several times because of asthma attacks. 
In the general emergency departments, the GPs always measure SpO2 and she had observed 
that the result was important in determining whether hospital treatment was required. She had 
bought a pulse oximeter and measured her children’s oxygen saturation when they had 
symptoms indicating an asthma attack. She was only able to speak in short phrases because of 
shortness of breath. The consultation ended with my referring her to hospital for treatment of 
her asthma attack. 
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2. Aim of the thesis 
2.1 Background 
This work was not initially planned as a PhD project. The first step was a quality assurance 
project in my own practice, including spirometry testing of patients with stable obstructive 
lung disease. During the writing process for this project, I encountered Hasse Melbye and the 
General Practice Research Unit in Tromsø. I was asked to participate in data collection in the 
DIOLUP (Better Diagnosis and Treatment in Exacerbations of Obstructive Lung Diseases in 
Primary Care) project. The first article from DIOLUP, not included in this PhD thesis, 
described the main baseline findings from the study (87). The aim was to describe lung 
function, symptoms during stable phases of illness, and diagnostic labels used in men and 
woman aged ³ 40 years. A spirometry-based diagnosis of COPD could be made in 68% of the 
patients with a previous COPD diagnosis and in 17% of those diagnosed with asthma alone. 
A diagnosis of COPD that cannot be confirmed by spirometry represents a challenge in 
clinical practice. The ability of GPs to differentiate between asthma and COPD has improved, 
probably because of the dissemination of spirometry and guidelines for COPD diagnosis. It is 
important in primary care to focus on diagnosing COPD, for which spirometry is useful 
because diagnosing COPD may lead to the patient quitting smoking (88). 
Pulse oximetry was one of the tests included in the data collection for the DIOLUP project 
and because of my interest in laboratory tests originating from my working in a clinical 
chemical laboratory (89), I seized the opportunity to work with those results. In this analysis 
process, an association between pulse oximetry and CHD was noted. This led me to the data 
from the Tromsø study (population-based survey), which has an emphasis on the 
epidemiology of cardio-vascular diseases. Then, the research question arose: “Is there a 
correlation between echocardiographic evidence of heart failure and low pulse oximetry 







The main aim of this thesis was to describe the utility of the diagnostic tests, spirometry and 
pulse oximetry, in primary care patients with stable obstructive lung disease. The detailed 
aims were as follows. 
1. To perform clinical audit including spirometry testing in my own general practice with the 
aim of quality assurance to ensure the correct prescription of ICS to patients with 
obstructive lung disease. 
2. To explore the associations between decreased pulse oximetry values (SpO2) and clinical, 
laboratory and demographic variables in general practice in patients diagnosed with 
obstructive lung disease. 
3. To investigate the association between decreased pulse oximetry values (SpO2) and 
echocardiographic measurements of diastolic ventricular dysfunction in a general 






















Study I: The Lillestrøm study 
The Lillestrøm study (Figure 6) was undertaken in one group practice in the Skedsmo 
community (52,600 inhabitants) in south-east Norway. From the electronic patient record 
(EPR) database of 8,100 patients listed with six GPs, all patients ³ 50 years old who had been 
prescribed ICS during the one-year period (1 October 2005 to 30 September 2006) before new 
terms for reimbursement of drug costs were introduced in Norway were identified (164 
patients). A letter about the new reimbursement regulations and an invitation to a tailored 
consultation with their GP were sent to 162 patients and 114 (69.5%) patients attended a 
consultation. Two were excluded from the study because of invalid spirometry. 
Study II: The Better Diagnosis and Treatment in Exacerbations of Obstructive 
Lung Diseases in Primary Care (DIOLUP) study 
The DIOLUP study (Figure 6) was carried out in seven Norwegian GP group practices from 
south-east and northern Norway. The practices were not randomly selected, but were chosen 
based on the availability of spirometry and the type of medical record system used. Of the 
43,241 patients listed at the seven practices, 18,931 were ³ 40 years old; among these, 1,784 
had been diagnosed by the GP with asthma and/or COPD within the previous five years. Each 
group practice decided the proportion of registered patients that they would invite to 
participate in the study. A total of 1,111 patients were invited to participate and in all the 
practices these were randomly selected in alphabetical order from the eligible patients. 
Invitations were sent by surface mail without additional reminders. Of the 1,111 patients 
invited, 380 (34.2%) accepted and attended the baseline examination including spirometry 
and pulse oximetry. Eight patients were excluded from analysis, two because they were 
undergoing an acute exacerbation, two because they did not complete post-bronchodilator 
spirometry and four because they did not undergo pulse oximetry. A total of 372 patients 
were included in the study. 
Study III: The Tromsø 6 study 
The Tromsø study (Figure 6) was initiated in 1974 (90). It is a repeated cross-sectional 
population-based study; the seventh survey was carried out in 2015–16. Tromsø is the largest 
city in northern Norway (70,000 inhabitants). In the sixth survey, Tromsø 6, carried out in 
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2007–2008, participants were recruited from four different invited groups. Of all those who 
took part in the second visit for Tromsø 4, a random 10% sample of inhabitants aged 30–39 
years, a random 40% sample of inhabitants aged 43–59 years and all inhabitants aged 40–42 
and 60–97 years were invited to participate, making a total of 19,762. The attendance rate was 
66% (12,984 individuals). Participants were invited to take part in a second visit for a more 
extended medical examination if they fulfilled one of the following criteria: they had attended 
the second visit in Tromsø 4, were aged 50–62 or 75–84 years, or were included in a random 
20% sample of inhabitants aged 63–74 years. Thus, 7,958 individuals were invited to take 
part in the second visit, and 7,307 did so (92% attendance rate). SpO2 was measured in 6,477 
of the participants who took part in the second visit and spirometry was performed in 6,437; 
11% did not complete the pulse oximetry and lung function testing because of technical 
problems or absence of staff. Participants in the second visit were randomly allocated to two 
lines of examinations, one of which included echocardiography by which 2,285 subjects were 
examined. Valid recordings for SpO2 and mitral Doppler inflow were obtained in 1,979 
participants. After excluding participants < 50 years (n = 188) and subjects with SpO2 < 70% 


































The Lillestrøm study (Figure 7) was a quality assurance project, with the main aim of 
evaluating whether ICS was correctly prescribed. Tailored consultations included the patients’ 
history, physical examination and spirometry with reversibility testing. The patients’ previous 
pulmonary diagnoses were recorded. Patients were instructed not to use any inhaled 
medications on the day of investigation prior to spirometry. The spirometry was carried out 
by trained staff in accordance with criteria of the American Thoracic Society (ATS)/European 
respiratory Society (ERS) (91). The spirometer used was a Microloop II with Spirare® 
software (Diagnostica AS, Oslo, Norway).  and the European Coal and Steel Community 
reference for spirometry was used (92). Reversibility tests were performed 20 minutes after 
patients inhaled 0.4 mg salbutamol. Reversibility was defined as increased FEV1 of ³ 12% 
and 200 ml (11). The spirometry criterion for COPD was based on the GOLD guidelines and 
was defined as a ratio of FEV1/FVC < 0.7 after bronchodilation (88). Based on FEV1% 
predicted, patients were categorized into COPD stages based on the GOLD guidelines (88). 
Data from the tailored consultation were recorded from each patient’s medical record. The 
decision about follow-up of findings was left to individual GPs in collaboration with their 
patients. In April 2008, 15 months after the audit was completed; a retrospective EPR data 
search was performed regarding GPs’ diagnoses and prescribing patterns for patients who had 








Participation in this part of the study required patients to complete a questionnaire and 
undergo a consultation during a stable phase of their disease for clinical examinations 
including spirometry. The participants were instructed not to take their regular respiratory 
medication on the day of the examination. The GPs recorded co-morbidities including CVD 
on a computerized questionnaire linked to the patients’ medical record. On a separate 
questionnaire, patients recorded their smoking habits. The patients’ height and weight were 
recorded to calculate their body mass index (BMI). Oxygen saturation was measured with an 
Onyx II® digital hand-held pulse oximeter (model 9550; Nonin Medical, Inc., Plymouth, MN, 
USA). The highest value obtained from three measurements was recorded. The HemoCue 
Hemoglobin system (Quest Diagnostics, Madison, NJ, USA) was used for haemoglobin 
measurements. The thresholds for raised values were based on the reference values used at the 
University Hospital of North Norway. The upper normal limit was 16.0 g/dL for women and 
17.0 g/dL for men. C-reactive protein (CRP) was analysed using an Afinion AS100 Analyser 
(Axis-Shield, Oslo, Norway), Orion Quickread CRP (Orion Diagnostica, Espoo, Finland) or 
ABX Micros CRP (Horiba ABX SAS, Montpellier, France), all of which could display values 
down to 8 mg/L. Spirometry was carried out after the pulse oximetry test, following 
ATS/ERS guidelines (91), using a Spirare SPS310 spirometer (Diagnostica AS, Oslo, 
Norway). During spirometry, the patients were seated, and a nose clip was not used. Post-
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bronchodilator spirometry was carried out 20 minutes after inhalation of 0.4 mg salbutamol. 
The post-bronchodilator FEV1 and FVC were used in the analyses. Norwegian reference 
values for spirometry were applied (93). 
Study III 
A questionnaire including questions about smoking habits, previous diseases and daily 
medication was enclosed with the letter of invitation to participate and was collected at the 
subsequent visit, during which height and weight were measured. Participants who reported 
having myocardial infarction or diabetes were classified as “self-reported” diabetes and “self-
reported” myocardial infarction. During the first examination, participants were given a 
second questionnaire, which they were instructed to complete and return by mail or to the 
examination site. The second questionnaire covered dyspnoea. Height and weight were 
measured in standing subjects wearing light clothing without shoes. BMI (in kg/m2) was 
calculated. 
SpO2 values were measured with an Onyx II® digital hand-held pulse oximeter (Nonin 
Medical, Inc.). Participants rested for at least 15 minutes before examination. The best of 
three measurements was recorded. The manufacturer’s testing has shown that only values 
between 70% and 100% are accurate to within ±2 digits, and therefore values below 70% 
were regarded as invalid. None of the participants received supplemental oxygen. 
After the pulse oximetry, spirometry was performed using a Vmax Encore 20® (VIASYS 
Healthcare Respiratory Technologies) and the ATS/ERS criteria were followed (91). 
Norwegian reference values were used (93). A reversibility test was not performed. The 
instrument was calibrated every morning and when demanded by the machine. Three trained 
technicians conducted the spirometry, which was performed with subjects in a sitting position 
and using a nose clip. The subjects were instructed to exhale for as hard and long as possible 
– for a minimum of 6 seconds. At least three exhalations were required. For a valid 
measurement, the difference between the highest and next highest FEV1 and FVC should not 
be > 150 mL (FVC £ 1.0 L, not exceeding 100 mL) or vary by > 5%. Current drug therapy 
was not interrupted before the test. The spirometry results were excluded if the test was not 
performed properly. The inclusion criteria were FEV1 > 0.3 L, forced expiratory volume in 3 
seconds (FEV3) ³ 0.0 L and FVC > FEV3. 
Echocardiographic measurements of systolic and diastolic left ventricular function were 
measured using a Vingmed CFM 750 (Vingmed Sound A/S, Horten, Norway) (Figure 8) with 
a combined 3.25 MHz mechanical and 2.5 MHz Doppler probe. The examinations were 
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performed by two expert cardiologists, using the standard apical and parasternal long- and 
short-axis views. Standard 2D-guided M-mode registrations of antero-posterior left atrium 
(LA) size, internal dimensions of the left ventricle (LV) and wall thickness of the septum and 
posterior wall were made using the leading-edge to leading-edge convention (94). The 
measurements of peak mitral flow velocity in early diastole (E-wave) and during atrial 
contraction (A-wave), the calculated E/A ratio and the E-wave deceleration time (EDT) were 
assessed online on one heart cycle. The influence of heart rate was minimized by measuring 
EDT as the time between the peak E-wave and the upper deceleration slope extrapolated to 
the zero baselines (95). TDI of the septum at the mitral annulus was performed with 
measurement of early diastolic mitral annular velocity (e¢) and subsequent calculation of 
average septal and lateral E/e¢. LVEF was measured in short axis (M-mode). LA size was 
indexed by body surface area (BSA) and systolic dysfunction defined as LVEF < 50%. A 
reproducibility study of the echocardiographic data was performed (96). 
 
Figure 8 
The Vingmed CFM 750 ultrasound system used in the Tromsø study. 
 
4.1 Statistics 
In Study I, frequency analyses were performed. Spirometry findings in the 112 patients 
treated with ICS were described as were the number of patients who continued or 
discontinued ICS. 
In Study II, we defined low pulse oximetry values as SpO2 £ 95%. SpO2 did not show a 
normal distribution and was dichotomized using two different thresholds: £ 92% and £ 95%. 
We compared the characteristics of two diagnostic groups of patients defined based on 
whether the GP’s diagnosis was coded as R96 (COPD) or R95 (asthma) according to the 
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International Classification for Primary Care (97). Patients who had been given both 
diagnoses within the previous 5 years were allocated to the COPD group. The significance of 
the differences in frequencies was analysed using the chi-squared test. The frequencies of 
decreased SpO2 were analysed according to age, sex, smoking habits, self-reported diseases, 
spirometry, BMI, CRP and haemoglobin. Continuous variables (age, BMI, FEV1% predicted, 
CRP and haemoglobin) were categorized. Categorization of the continuous variables was 
made before analysis and with clinical justification (98) to facilitate presentation and 
interpretation of findings. Age was dichotomized into < 65 years and ³ 65 years. BMI was 
categorized as underweight (< 20 kg/m2), normal weight/overweight (20–30 kg/m2) and obese 
(³ 30 kg/m2) (99). The FEV1% predicted was categorized as severely reduced (< 50%), 
moderately reduced (50–80%) and normal (³ 80%), in line with the GOLD classification for 
COPD (38). CRP values were dichotomized into ³ 8 mg/mL and < 8 mg/mL. Haemoglobin 
values were dichotomized into above normal (> 16.0 g/dL in women and >17.0 g/dL in men) 
and normal and low (£ 16.0 g/dL in women and £ 17.0 g/dL in men). Age, sex, and variables 
significantly associated with a decreased SpO2 (P < 0.05) in the chi-squared test were entered 
into a multivariable binary logistic regression. The multivariable analysis was also performed 
without categorizing the continuous variables. 
In Study III, the characteristics of the study population were compared by sex, and the 
differences were explored by independent-sample t test (for continuous variables) and chi-
squared test (for categorical variables). The frequency of abnormal mitral Doppler inflow was 
analysed by sex, smoking status, self-reported diseases (myocardial infarction and diabetes), 
dyspnoea, hypertension, spirometry, BMI, LVEF < 50% and SpO2 £ 95%. The significance of 
differences was analysed by a chi-squared test. BMI, LVEF and SpO2 were dichotomized. 
Because of the small number of participants with dyspnoea categorized as moderate, severe 
and very severe, these three categories were merged into one category. The FEV1% predicted 
was categorized as indicated by the GOLD classification (9). 
The analysis proceeded in two steps. First, univariable binary logistic regression models were 
fitted to the data to identify variables that were associated with abnormal mitral Doppler 
inflow. Second, variables with P £ 0.1 in the univariable analyses were entered into the 
multivariable binary logistic regression models. The explanatory variable dyspnoea was 
included in model 2, but not in model 1. 
For Study I, the analyses were performed using IBM SPSS Statistics version 17, while 
version 18 was used for Study II and version 22 for Study III. 
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5. Summaries of the papers and main results 
5.1 Paper I 
Paper I included 112 patients from one GP group practice who were aged ³ 50 years and had 
been prescribed ICS (including in combination with long-acting beta-2 agonists) the year 
before the 2006 regulation for drug-cost reimbursement for ICS prescription according to 
which it became mandatory that the diagnosis was confirmed by spirometry. The principle 
became that costs for ICS should only be reimbursed with a diagnosis of asthma. Patients 
with COPD could also be reimbursed, but only after a special and individual application, and 
mainly for those with severe COPD (FEV1% predicted < 50). The 112 patients were invited to 
a tailored consultation including post-bronchodilator spirometry. Fifteen months after the 
audit was completed; a retrospective EPR data search was performed for GPs’ diagnoses and 
prescribing patterns for the 112 patients who had participated in the clinical audit. 
The spirometry results showed post-bronchodilator airflow limitation indicating COPD 
(FEV1/FVC < 0.7) in 55 patients. Reversibility ³ 12% and 200 mL was found in 13 patients, 
of whom eight also met the spirometry criteria for COPD. The number of patients diagnosed 
with asthma increased (from 25 to 62) after the reassessment. Because of the non-
standardized way in which different GPs diagnosed asthma, we found the statistical analysis 
to be of limited value, and it was not included in the final version of the paper. ICS was 
discontinued in 31 patients; 20 with spirometry results indicating mild to moderate COPD and 
11 with normal spirometry. Seven of these 11 had no history, symptoms or signs indicating 
obstructive lung disease, and the remaining four had episodic asthma without the need for 
long-term ICS treatment. Only one patient who had ICS treatment discontinued restarted this 
medication within the following year. 
This audit found that spirometry was useful for identifying ICS overuse. GPs’ diagnoses were 
challenged by the formal regulations and there was a tendency to adjust the diagnosis to the 
treatment given, instead of vice versa. 
5.2 Paper II 
Paper II included 372 patients aged ³ 40 years from seven Norwegian GP group practices, 
who were diagnosed by their GP with asthma and/or COPD. The patients were examined 
during a stable phase of their disease. Patients diagnosed with COPD (including those with 
combined COPD/asthma) and those with asthma only were analysed separately. Two 
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thresholds of abnormal SpO2 values were used as outcome measures: £ 95% and £ 92%. In 
both asthma and COPD patients, SpO2 £ 95% was significantly associated with reduced lung 
function (FEV1% predicted £ 80%), a self-reported diagnosis of CHD and older age (³ 65 
years). In the COPD group, haemoglobin above normal was associated with SpO2 £ 95%. The 
binary multivariable logistic regression confirmed these associations, including the 
association with CHD. The most important predictor of low SpO2 £ 95% was FEV1% 
predicted < 50%, which had an odds ratio (OR) of 6.8. Multivariable analysis with SpO2 < 
92% as outcome was not performed because of the low number of patients with such values 
(n = 11). 
The study concluded that patients in general practice asthma and/or COPD who had low 
oxygen saturation (SpO2 £ 95%) should be given special attention and followed up more 
closely than patients with normal oxygen saturation. The GP should consider revising the 
diagnosis and treatment and look for co-morbid CHD. 
5.3 Paper III 
Paper III included 1,782 participants from a population-based survey, Tromsø 6, aged ³ 50 
years who had been evaluated with pulse oximetry and echocardiography. The primary 
outcome was left ventricular DD. Mitral Doppler indices were used for evaluating DD. The 
associations between this outcome and possible predictors, including SpO2 £ 95%, were 
analysed using univariable and multivariable logistic regression. DD was found in 595 
participants. Male sex, self-reported myocardial infarction, dyspnoea, former smoker, 
hypertension, BMI ³ 30 and SpO2 £ 95% were all significant predictors of abnormal mitral 
Doppler flow in the multivariable analyses. SpO2 £ 95% was an independent predictor for DD 
with an OR of 1.6. Hypertension and BMI ³ 30 significantly predicted impaired filling with 
ORs of 1.7 and 1.5, respectively. 
The study concluded that DD should be included among possible explanations when 
decreased oxygen saturation is found. 
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6. General discussion 
6.1 Methodological considerations 
The three studies are based on data from one GP group practice, seven non-randomly selected 
GP group practices and a population-based survey. All three studies must be critically 
assessed for bias because of both the design and the conduct of the studies. Internal and 
external validity are required for generalization beyond the study populations (100). 
6.1.1 Internal validity 
Internal validity refers to scientific interference within the study population; it implies bias in 
the way the data is collected, analysed or interpreted. Three major types of error can influence 
internal validity: selection bias, information bias and confounding (100). 
Selection bias concerns the representativeness of the study participants in relation to the 
source population. Selection bias can result from procedures used to select study participants 
or other factors influencing study participation (101). Selection bias is present when people 
have different probabilities of being included in the study sample according to relevant study 
characteristics (102). If the association between exposure and outcome is different in those 
who participate in the study compared with those who choose not to participate, the effect 
estimates from the study will differ from those existing in the source population (100). 
Information bias results from a systematic tendency for participants selected for inclusion in 
the study to be erroneously placed in different exposure/outcome categories, thus leading to 
misclassification (102). When we study categorical variables, the misclassification can be 
either differential or non-differential (100). Differential misclassification occurs when 
incorrect classification of a variable depends on the value of other variables. Such 
misclassification can either exaggerate or under-estimate the effects in a study. Recall bias is 
an example of differential misclassification that results from inaccurate recall of past exposure 
(102). Non-differential misclassification arises when incorrect classification of a variable is 
unrelated to other variables and is identical for all study subjects. Such misclassification can 
dilute the strength of the associations between groups in a study, thereby biasing the 
association towards the null hypothesis (99, 100, 102). 
In Studies II and III, questionnaires were used for some of the variables (smoking habits, self-
reported diseases, dyspnoea and blood pressure treatment). Differential misclassification may 
occur when the patient is asked about an event a long time after it occurred (recall bias) (102), 
and this may influence the sensitivity and/or specificity of the questions. This could bias the 
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results of the study, but it is a particular concern in case–control studies, when cases and 
controls are asked about exposures in the past. 
Questions about smoking habits may have been a difficult topic for some participants who 
may feel stigmatized by their habit, which could lead to inaccurate answers. Therefore, there 
may have been bias in categorizing smokers, former smokers and never smokers. However, 
self-reports of smoking are usually accurate (103, 104). 
Non-differential misclassification might have occurred when we chose to categorize some of 
the variables in Studies II and III (outcome variables SpO2 and mitral Doppler inflow, age, 
CRP, dyspnoea, FEV1% predicted, BMI, haemoglobin, LVEF, LA diameter/BSA and 
abnormal ratio of TDI and mitral passive inflow E/e¢). Although such misclassification could 
have resulted in a dilution of associations (100), it is probably more likely that the results are 
an under-estimation than an overestimation (105). 
Measurement error can be mismeasurement of a quantitative variable, or misclassification of 
a categorical variable. These errors are typically the result of instrument error and/or sampling 
error (101). Instrument error arises when we are unable to measure a specific quantity defined 
at a specific point because of limitations of the measuring device used. Errors are classified as 
differential (systematic) or non-differential (random). Accuracy of measurement can be 
achieved through minimizing systematic error and random error (high validity and reliability). 
Validity is the ability of a test to indicate which individuals have the disease and which do 
not. Reliability is the degree to which an assessment tool produces stable and consistent 
results. 
Spirometry 
Spirometry was performed in all three studies, but the instrument used varied. In Study I, 
spirometry was performed using a Microloop II spirometer with Spirare® software; in Study 
II, with a Spirare SPS310 spirometer; and in Study III with a Vmax Encore 20® spirometer. 
The Spirare SPS310 sensor uses bidirectional ultrasound transit time measurements. 
Spirometric indices obtained by trained general practice staff using the Microloop II with 
Spirare® software are justifiably comparable with those measured in a pulmonary function 
laboratory (106). The digital technology makes recalibration obsolete, although a sensor 
quality control routine is included. The spirometers used in Studies I and II did not require 
daily calibration (and it was technically not possible to adjust the spirometers in the 
practices), but spirometric values should be checked either by a calibration pump or by using 
a biological control (a healthy person working in the laboratory). We have no information 
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about how regularly this was carried out in the GP offices participating in Studies I and II. In 
Norway, guidelines recommend an official agency for quality control of spirometers and 
spirometry examinations in the health services (76), but this is not yet established. 
In Study I, the spirometry was carried out by trained staff at the GP’s office. The staff in this 
six-GP practice had attended a course that included professional tuition on the practical 
application of spirometry. Accurate spirometry was also ensured by appropriate training 
during the years before this audit. Results were excluded if the spirometry was not performed 
adequately (two results in Study I and two in Study II, which accounted for 1.8% of the total 
Study I sample and 0.5% of the total Study II sample). 
In Study III (Tromsø 6), calibration of the instrument was performed every morning and when 
prompted by the machine. Three trained technicians conducted the spirometry. If the 
spirometry was not performed adequately, the results were excluded (19 results in Study III, 
which accounted for 1.1% of the total sample in Study III). 
A limitation is involved in the validity of the reference values when they are applied in the 
oldest age group, and this might have played a role in Study III in which a high number of 
participants were aged ³ 75 years (24.0%). However, this factor was minimized by 
categorizing FEV1% predicted in the analysis. 
Day-to-day variability of FEV1% predicted, expressed by the coefficient of variation (CV), is 
higher in COPD patients (2.8%) and clinically stable asthma patients (2.3%) than in healthy 
individuals (0.7%) (107). This could be a differential error because the probability of being 
misclassified differed across the groups of audit subjects. In Study I, 49% had a post-
bronchodilator FEV1/FVC < 0.7 indicating COPD, and most of the patients in Study II had 
either COPD or stable asthma. In addition, the FEV1% predicted was categorized for analysis 
in all three studies, which should have minimized this potential error. 
A nose clip was only used in Study III. Use of nose clips during spirometry does not 
systematically affect the results obtained or the within-subject repeatability (108). The use of 
a nose clip is uncommon in primary care. 
Pulse oximetry 
Pulse oximetry was performed in Studies II and III. SpO2 was measured in resting patients in 
Study II and in resting participants in Study III. In Study II, the patients completed two 
questionnaires in the waiting room before SpO2 measurement; in Study III, the participants 
had been waiting in a queue or had been to other non-demanding examinations. Accordingly, 
the participants/patients rested for at least 15 minutes before the examination, and the best of 
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three measurements was recorded. Correct probe placement was checked, and a green light 
indicated a valid measurement. Accuracy is reduced with SpO2 values < 70% (69); nine 
participants in Study III and none in Study II were excluded because of this. 
Pulse oximetry measurements have limitations that can cause false SpO2 values, either lower 
or higher (71, 109, 110). Although pulse oximeters do not require user calibration, awareness 
of their inherent limitations is important (110). Possible causes and mechanisms of unreliable 
SpO2 readings are as follows. 
• Causes of intermittent drop-outs or inability to read SpO2: poor peripheral perfusion (e.g., 
hypovolaemia, vaso-constriction), cold extremities or hypothermia. 
• Causes of falsely normal or elevated SpO2 readings: CO poisoning and sickle cell anaemia 
vaso-occlusive crises (71). 
• Causes of falsely low SpO2 readings: venous pulsations, excessive movement, intravenous 
pigmented dyes, inherited forms of abnormal haemoglobin, dark fingernail polish, severe 
anaemia (with concomitant hypoxaemia). 
• Causes of falsely low or high SpO2 readings: methaemoglobinaemia, 
sulfhaemoglobinaemia, poor probe positioning, sepsis and septic shock. 
• CO poisoning in chronic heavy smokers (can achieve up to 10% arterial 
carboxyhaemoglobin), which may overestimate SpO2 (111, 112). 
• Different nail polish colours may cause lower pulse oximeter readings (109, 113), although 
a systematic review concluded that the changes in SpO2 readings were not clinically 
significant (114). 
• Exposure to strong external light while taking measurements may result in inaccurate 
readings, so it is important to shield the sensors from bright light. 
In Studies II and III, errors may have led to overestimated readings in heavy smokers and in 
people with type 2 diabetes and possibly high haemoglobin A1C levels, and under-estimated 
readings in people wearing nail polish. Current smoking was associated with decreased SpO2 
in our studies, and high CO levels in smokers were probably not an important source of bias. 
The reliability of the measurement was improved by using the highest of three measurements. 
Confounding and effect modification (interaction) 
A confounder is commonly defined as a variable that could influence the outcome and at the 
same time could be associated with exposure (101). Three conditions must apply to a 
confounding factor: the association between the factor and the outcome must come from a 
causal pathway other than the main exposure; the factor must also be associated with the 
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exposure; and the factor must not be an intermediate step in the causal pathway between the 
exposure and the outcome. A confounding factor can cause both under-estimation and 
overestimation of the outcome variable (100). An example is the influence of 
carboxyhaemoglobin concentration on SpO2, which can lead to overestimation of the actual 
SaO2 (115). Once inhaled, CO can bind to haemoglobin to form carboxyhaemoglobin, 
reducing the oxygen-carrying capacity of the red blood cells by direct competition for the 
binding sites. Hypoxia occurs, and secondarily, the number of red blood cells increases. The 
result may be that the measured haemoglobin value increases. 
Randomization, multivariate adjustment, stratification, subject restriction and matching are 
common methods used to control for potential confounding factors in studies. Double-blind 
randomized trials are the gold standard when it comes to avoiding confusion of effects 
because this method allows the comparison of groups with common background 
characteristics. In our studies, there was no randomization. 
The significance of the differences was first analysed by chi-squared test, after categorizing 
continuous variables, and by the independent-sample t test for continuous variables. In Study 
III, the data were stratified to determine whether there were any differences between men and 
women. In the Tromsø 6 study, men had significantly lower SpO2 values (116), and this was 
also shown in Study III with participants recruited from Tromsø 6. The explanation for higher 
oxygen saturation in morbidly obese, (BMI ³ 40 kg/m2) women than in morbidly obese men 
is that women have less abdominal obesity, and abdominal obesity is associated with reduced 
gas exchange (117). In Study III, this effect of male sex may have been reduced if we had 
included waist-to-hip ratio in the analysis. Dyspnoea was more frequently reported in women, 
and although mild dyspnoea was not a significant predictor in the multivariable analyses, this 
might have been influenced by the sex effect. 
The method that was applied in Studies II and III to avoid confounding was multivariable 
analyses. Logistic regression is a mathematical method that gives an adjusted OR, which 
means that its value has been adjusted for the other covariates, including confounders (118). 
We chose logistic regression analysis because it allowed us to predict categorical outcomes. 
In Study II, predictors of low SpO2 with a significance of < 5% (except low BMI, which was 
only significant in the COPD group) were entered into the multivariable binary logistic 
regression. In Study III, variables associated with DD (P £ 0.01) in the univariable binary 
logistic regression analysis were entered in the final multivariable logistic regression models. 
It is also important that there was no multicollinearity among the predictor variables. 
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Interaction describes a situation in which two or more risk factors modify the effect of each 
other with regard to the occurrence or level of a given outcome, that is, effect modification. 
There can be positive or negative interactions (102). We did not check for interactions in the 
categorized multivariable regression used in this study. All the variables in the multivariable 
analyses were categorized, except age. 
All statistical tests involve the possibility of making type I and type II errors. A type I error is 
the incorrect rejection of a true null hypothesis, and this can lead to the conclusion that an 
association exists when in fact it does not. This may be solved by shifting the significance 
level from 0.05 to 0.01, thereby reducing the chance of a type I error from 5% to 1%. A type 
II error is the failure to reject a false null hypothesis. The risk of committing a type II error is 
decreased by ensuring that the test has sufficient power, which can be increased with a larger 
sample size. In logistic regression models, the risk of a type II error increases with the number 
of variables included in the models because the degrees of freedom decrease, and thus the 
power decreases (100). Excluding relevant variables from the logistic regression model will 
lead to biased estimates, and including irrelevant variables may increase the standard error, 
increasing the risk of type II error. 
Effect modification occurs when the effect measure varies across levels of another variable. 
This is not a bias, but an important finding that should be reported and not corrected for. 
There is a positive interaction if the presence of the effect modifier strengthens the effect of 
the exposure of interest, and a negative interaction is where the presence of the effect modifier 
diminishes or eliminates the effect of the exposure of interest (102). In Study II, we checked 
for interactions between age and the other predictors, and found no significant interactions. 
Confounding can persist also after adjustment. There could be unknown confounders and 
confounders not measured during the process of data gathering (118). 
Statistical power depends on statistical significance; in Studies II and III, the statistical 
significance level was set to 0.05 (5%). 
6.1.2 External validity 
The external validity or generalizability of a study refers to the ability to apply the results 
from a study to people outside the study population (119). To achieve a high external validity, 
it is important that the study sample is representative of other groups in the population or of 
other populations. 
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6.2 Study I 
6.2.1 Introduction 
The main finding from the Lillestrøm study was that the GPs’ diagnostic practice changed 
after implementation of new reimbursement terms and the audit suggested that there was 
overtreatment with ICS in middle-aged and older patients. 
The numbers of patients with an asthma diagnosis more than doubled after the tailored 
consultations. This could represent a tendency to adjust the diagnosis to the treatment given, 
but it was also an opportunity for the use of spirometry in the tailored consultations to 
improve the accuracy of diagnosis of the patients. 
Use of the EPRs was helpful in this project to identify a group of patients, and may also be 
useful in other projects in general practice. The study shows that spirometry should be 
performed in all GP offices. 
6.2.2 Methodological considerations 
The Lillestrøm survey of one GP group practice included a limited number of patients and the 
validity of the extrapolation to Norwegian general practices depends on the representativeness 
of the patient sample and of the six GPs working in this general practice. The sample 
estimates may differ substantially from the true parameters because of random error, 
especially when the study sample is small (102). 
The Lillestrøm study was a descriptive study used to describe the characteristics of patients in 
one group GP practice who were prescribed ICS. Descriptive research cannot identify 
causality of the observations. This was also a longitudinal non-randomized intervention study 
reporting the therapeutic responses as findings. 
Audit or research? 
The Lillestrøm study was classified as a quality assurance project. However, research and 
audit have many similarities. They both start with a question, both expect the answer to 
change or influence clinical practice, both require formal collection of patient data, and both 
depend on using an appropriate method and design to reach sound conclusions (120). The 
major distinction between audit and research is that research aims to generate new knowledge 
about health and disease (121), whereas audit investigates whether the aims of the practice 
have been achieved (122). Unlike research, clinical audit projects do not need to be submitted 
to a Research Ethics Committee (REC) for ethical approval because clinical audit does not 
involve anything being done to patients beyond their routine clinical management. We asked 
the question: “Are we following the best practice?” As for research, an ethical framework is 
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important in a clinical audit, which means ensuring patient confidentiality and that data are 
collected and stored appropriately. 
The standards for audit in terms of design, data collection and analysis should be the same as 
those for research; audit leads to change more often than research does (120). In the 
Lillestrøm study, we investigated how changed terms for drug payment influenced GPs’ 
diagnoses and their prescribing practice for ICS. The results of the tailored consultations with 
their patients on GP diagnoses and prescribing patterns were assessed by a retrospective EPR 
data search after the clinical audit was finished. The decision about discontinuation of ICS 
and follow-up of findings was left to individual GPs in collaboration with their patients. A 
new retrospective EPR data search of the patients who discontinued ICS was performed 15 
months after the audit. One patient had restarted ICS because of relapse of asthma. 
Decisions about whether a project is a clinical audit or research are not straightforward; we 
presented the audit for retrospective evaluation by the Regional Committee for Medical and 
Health Research Ethics, South-East Norway, who agreed that this was a clinical audit. 
6.2.3 Internal validity 
Selection bias 
In this quality assurance project, 70% (114 of the 164) of the invited patients attended the 
study. Of the 50 non-participants, 14 no longer used ICS, which indicates that they were 
healthier than the participants. Three patients were too ill to participate, one was followed up 
at the hospital, two were deceased and one letter was returned because of an unknown 
address. 
Information bias 
No questionnaire results were used in this report; the diagnoses of asthma and COPD were 
recorded from the EPR database. The quality of the GPs’ diagnoses could be questioned. 
Measurement errors 
Spirometer measurement error is described in section 6.1.1. 
Statistical power 
In Study I, the sample size was small and from only one GP practice. Associations are harder 
to detect in smaller samples. Random errors occur because the associations we observe are 
based on samples, and samples may not accurately reflect the population at large. In large 
samples, random errors have less impact. The diagnostic criteria for asthma were not 
standardized, limiting the value of statistical assessment. 
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The participation rate was 69.5%. A high participation rate is important for internal validity. 
6.2.4 External validity 
The Lillestrøm study included a limited number of patients and the validity of its 
extrapolation to Norwegian general practices depends on the representativeness of the sample 
of patients, the GPs and the place and time it took place. The group practice had six GPs 
whose mean age was 50 years, three (50%) of the GPs were female, and each GP had a 
patient list of 1,500. This is relatively close to the average in Norway in 2006 where the mean 
age of GPs was 48 years, 31% of GPs were female and the average patient list was 1,196 
(123). One of the GPs had a long-term interest in obstructive pulmonary diseases, and the 
performance of the practice in this field was not inferior to the average Norwegian general 
practice. Lillestrøm is a town of 12,500 inhabitants in the outer ring of Oslo; in 2006, it had a 
population of 5.9% non-Western immigrants and 3.6% Western immigrants (124). This study 
was undertaken 3–6 months after it became mandatory that for drug-cost reimbursement for 
asthma/COPD, the diagnosis must be confirmed with spirometry. Therefore, because of this 
change, the GPs could have had a consultation with their patients before our tailored 
consultation. Hence, we believe that our study sample from one group practice is applicable to 
other Norwegian urban GP practices. 
6.2.4 Strengths of Study I 
This practice-based clinical audit with an invitation to a tailored consultation including 
spirometry for all patients > 50 years who were using ICS was a way of improving the quality 
of treatment and diagnosis. Our aim was to improve the quality of health care; only one 
patient who ceased ICS had to restart the treatment. The audit including spirometry led to 
revised treatment in more than a quarter of the patients on ICS therapy. 
 6.2.5 Limitations of Study I 
Study I had a number of limitations. 
1. The main limitation was the low number of patients and GPs who were all from the same 
GP group practice. Thus, caution is required in drawing the conclusion that these findings 
are representative of Norwegian general practice. 
2. With respect to internal validity, the participant rate was 69.5%: 27 (54%) of the 50 non-
responders among those invited to participate no longer used ICS or had only a single ICS 
prescription. These patients probably considered that there was no advantage in 
participating in a quality assurance study to monitor use of a medication they no longer 
used. 
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3. Sixty-nine (61.6%) patients did not have a diagnosis of asthma and/or COPD when they 
were prescribed ICS during the year before the tailored consultation. Other diagnoses were 
bronchitis, chronic cough, breathing problems and pulmonary fibrosis. After the audit, only 
21 (18.8%) of the patients had a diagnosis other than asthma and/or COPD. These figures 
are based only on the GP diagnosis recorded in the EPR and are not considered in the 
context of spirometry results and patient history in the EPR. This is a major weakness of 
the study and makes it difficult to interpret the results. However, we know that 25 of the 62 
patients given a diagnosis of asthma after the audit had spirometry findings suggesting 
COPD (FEV1/FVC < 0.7). Some of these 25 patients may have “asthma–COPD overlap 
syndrome” (ACOS), a condition in which a patient has clinical features of both asthma and 
COPD (125). The syndrome is estimated to be present in 15–45% of the population with 
obstructive airway disease (125). It is difficult to provide treatment guidance for patients 
with ACOS because of the lack of randomized intervention studies, but treatment with ICS 
is probably appropriate in patients with long-standing asthma even if a component of 
irreversible airway obstruction develops (125). 
4. The results of the statistical analysis described in Paper I (“The distribution of the GPs’ 
diagnoses recorded in EPRs changed significantly after the implementation of the new 
reimbursement terms”) were not specified in Table 2 of that publication. 
6.3 Study II 
6.3.1 Introduction 
The main finding from general practice including patients with stable asthma and/or COPD 
was that decreased pulse oximetry values (SpO2 £ 95%) were associated with both reduced 
lung function (spirometry test) and with a diagnosis of CHD. In Study II, the GPs recorded 
co-morbidities in the patients, including CHD. In both asthma and COPD patients, CHD was 
a significant predictor of decreased pulse oximetry values. 
Despite the increasing use of pulse oximetry in family practices, current clinical guidelines do 
not inform the GPs how to deal with SpO2 values £ 95%. Such values in patients in general 
practice who have stable asthma and/or COPD may prompt the GPs to consider whether the 
patients are receiving adequate treatment and/or have undiagnosed co-morbidity. Cardiac co-
morbidities are frequent in patients with COPD and influence its severity and prognosis. 
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6.3.2 Methodological considerations 
The study was carried out at seven GP group practices. The number of patients in each 
practice that were invited to participate was decided based on the workload associated with 
each patient, as well as the capacity for such tasks at each office (87). The GP offices 
volunteered to take part in the DIOLUP study and might not be representative of Norwegian 
practices (87). 
6.3.3 Internal validity 
Selection bias 
In this study carried out at seven dedicated GP offices, the participation rate was only 34% 
(380 of the 1,111 participants invited); therefore, it cannot be assumed that the study sample 
was representative of the background population. Patients who had been given a diagnosis of 
both asthma and COPD participated much more frequently than those with a single diagnosis 
of COPD (87). A double diagnosis may reflect frequent visits to the practice and accordingly 
more severe illness. The low participation rate among those with a single diagnosis of COPD 
may reflect that the most severely impaired COPD patients were less inclined to participate 
(87). This could be because they were followed up by a pulmonary specialist or in a 
pulmonary outpatient clinic in hospital. However, patients who had once had a diagnosis of 
asthma or COPD but now felt healthy might also have been less interested in taking part in 
the study (87). Thus, the study could have had selection biases away from both the most ill 
and the healthiest patients. However, such selection biases probably had little influence on the 
main findings of the study in terms of associations between explanatory variables and 
outcome. In Study II, there were very few patients with missing results (< 1% in multivariable 
analysis) and missing data are a negligible problem. 
Measurement errors 
Pulse oximeter error is described in 6.1.1. 
BMI 
Weight and height were measured by dedicated health secretaries in the seven different GP 
offices. BMI was calculated using a standardized method. Incorrect calibration of body 
weight may cause systematic error if the sensitivity and specificity vary between different 
ranges of the scale. Different types of scales were used for weight measurement in Study II 
and there could be a systematic error between the instruments. 
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Haemoglobin 
Haemoglobin was analysed from venous blood samples drawn from the cubital vein. In Study 
II, the HemoCue Hemoglobin system was used. Blood samples were drawn by a medical 
technologist or other qualified person while the patients were in a sitting position. The 
samples were analysed within 24 hours. All blood samples for haematological analysis were 
stored at room temperature until analysed in the GP’s office. The reference method for the 
measurement of haemoglobin is based on the spectrophotometry characteristics of 
haemoglobin cyanide (126). Point-of-care testing with HemoCue was used; this method uses 
a modified azide methaemoglobin reaction to spectrophotometrically measure total 
haemoglobin. The most common source of error in haemoglobin measurement is the 
treatment of the reagents. Internal quality control of the HemoCue photometer was checked 
on a daily basis using the control cuvette and a standard of known concentration and external 
quality control was performed by the Norwegian Quality Improvement of Laboratory 
Examinations (Noklus) organization using control material sent to the GPs’ offices twice a 
year. 
CRP 
CRP was analysed from whole blood in Study II. Blood was drawn in the same way as 
described above for haemoglobin. There is no agreed reference method for CRP analysis. The 
range of CRP concentrations that can be encountered is wide, and one source of error is the 
high-dose hook effect at very high values. CRP was analysed using point-of-care testing 
(immunoturbidimetric) using an Afinion AS100 Analyser (analytical CV 6%), Orion 
Quickread CRP (analytical CV 5%) and ABX Micros CRP (analytical CV 3%). The 
analytical CVs for these three CRP test devices were obtained from Noklus. The advantages 
of these assays is that they are fully automated, rapid, and reproducible; however, they have a 
lower detection limit of around 5 mg/L, which precludes their use in risk assessment for 
CHD, where significant changes in the range of 0.5–3.5 mg/L have been reported (127).  
Statistical power 
Statistical power depends on statistical significance, and in Study II the statistical significance 
level was set at 0.05 (5%). The statistical power also depends on the prevalence of the 
outcome and the effect size. The prevalence of SpO2 £ 95% was 22.0% in Study II. 
The sample size in Study II was 372 patients. Associations are more difficult to detect in 
smaller samples. Random error occurs because the associations we observe are based on 
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samples, and samples may not accurately reflect the population at large. In large samples, 
random errors have less impact. 
In the multiple regression analysis, we included several covariates and the power for detecting 
an effect of a given size is related to the variance of the covariate. Because different 
covariates will have different variances, their powers will also differ. 
The participation rate was only 34% in Study II. A high participation rate is important for 
internal validity, and in Study II, it cannot be assumed that the study sample was 
representative of the background population. This selection bias in Study II may have 
influenced the prevalence of low SpO2 values but it probably did not influence the main 
findings of associations between decreased SpO2, reduced lung function and co-morbid CHD. 
6.3.4 External validity 
The DIOLUP study was carried out at seven GP group practices that were not randomly 
selected but were chosen based on the availability of spirometry and the type of electronic 
medical record used. This may have influenced the generalizability (external validity) of the 
study results because the GP offices might not be representative of Norwegian practices. In 
three of the seven offices, the GPs had special interests in spirometry and obstructive lung 
diseases. 
6.3.5 Strengths of Study II 
GP patients were included from different areas of Norway, from both city and rural areas. In 
general practice, it may be difficult to differentiate asthma and COPD (87), and the inclusion 
of patients diagnosed with either or both of these conditions makes our results relevant for 
patients with obstructive lung diseases in primary care. This reflects daily clinical practice in 
which the GP examines patients with stable asthma and/or COPD. There is no information in 
current guidelines about how GPs should deal with moderately decreased oxygen saturation 
(SpO2 £ 95%) in stable patients with asthma/COPD, and this study initiated the work required 
to help GPs to interpret values from pulse oximetry measurements in the follow-up for these 
patients. 
6.3.6 Limitations of Study II 
The main limitation was the low participation rate (34%), which implies that the study sample 
may not be representative of patients in general practice with asthma and COPD. However, 
the low participation rate is not likely to have substantially influenced the associations 
between decreased SpO2 values and the predictors (128). 
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6.4 Study III 
6.4.1 Introduction 
To find out more about the association between low oxygen saturation and heart disease, we 
chose to examine this relationship in an epidemiological study, the Tromsø 6. We used DD as 
the outcome measure. DD is a common finding in the elderly and a known result of 
hypertension and CHD. The relationship between low pulse oximetry values and 
echocardiographic indicators of left ventricular filling was examined. Low oxygen saturation 
was independently associated with abnormal mitral Doppler flow as a measure of DD. DD 
should be considered as a possible cause of moderately decreased pulse oximetry values. 
6.4.2 Methodological considerations 
The Tromsø study is population-based, a term that is traditionally used to describe a study 
that involves a defined “general population”. The common usage of the term implies 
sampling of individuals from the general population. 
6.4.3 Internal validity 
Selection bias 
In Tromsø 6, 66% of those invited participated in the first visit and 92% of those invited to 
the second visit attended, which represents a moderate decrease in participation rates from 
earlier Tromsø studies. People were sent reminders and social media was used to improve the 
participation rate. One reason for non-participation may be a lack of time: more 
comprehensive data collection, for example, from the echocardiography examination, means 
that the second visit is more time-consuming. 
Most non-participants were in the youngest and oldest age groups and in men. Severe co-
morbidity among non-participants may be the reason for the low participation rate in the 
oldest age group, and the effect of age could have been under-estimated. The most ill and the 
oldest participants may have had difficulty with transport to the central location where 
Tromsø 6 took place. Some people are concerned about issues with data security and may not 
want to provide informed consent to have their data stored in a database. Because there are 
few short-term benefits from health surveys, healthy age groups are less willing to participate. 
Some people are afraid of personal discomfort and so do not want to participate. The 
education level of the participants was higher than that of the general Norwegian population 
and the Tromsø population (90). The subjects who attended the first visit were given a second 
questionnaire that they were asked to complete and return by mail and 88.2% did so. The 
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responders tended to be married, non-smokers and to report respiratory symptoms less often 
than non-responders (129). The Tromsø study is comparable with the Nord-Trøndelag Health 
(HUNT) study. In that study, non-participants had lower socio-economic status, higher 
mortality and a higher prevalence of several diseases including COPD and myocardial 
infarction than participants (130). Non-participants in HUNT 3 had poorer general health, and 
a less healthy lifestyle in terms of tobacco smoking and physical inactivity (130). Non-
response bias is a major concern for studies based on data collected through questionnaires 
and the differences described above may lead to bias in prevalence estimates and bias in 
associations. However, in a study from the Netherlands, no differences were found between 
respondents and non-respondents for the associations between smoking or socio-economic 
status and subjective health (131), and non-response did not cause bias in the examined 
associations. 
Participants with missing data are a common and unavoidable problem in clinical and 
epidemiological studies (101). This is problematic because methods for statistical analysis 
assume that the data are complete. There are many reasons for missing data; examples from 
our studies include a participant failing to complete some of the items on a questionnaire, the 
laboratory/test personnel forgetting to do a test (e.g., of a blood sample, BMI measurement) 
or the tests are technically unsatisfactory (e.g., pulse oximetry, spirometry, 
echocardiography). We have excluded participants with missing data from our univariable 
and multivariable analyses. This is called complete case analysis (101), and usually introduces 
bias unless the data are randomly missing. In our analysis, it is difficult to justify that the 
missing data are completely random. In addition, we lost information because we discarded 
the incomplete observations, which might have resulted in decreased precision in our results. 
However, if the proportion of missing data is very low, little harm is done by using the 
complete case analysis method instead of more complicated missing data methods (132). In 
Study III, there were missing data (3.8% in the multivariable analysis); an alternative 
approach to deleting cases would have been imputation, in which missing values are replaced 
by some plausible value predicted from that individual’s available data (132). 
Measurement errors 
Echocardiography  
The various sources of measurement variability need to be considered when applying cardio-
vascular ultrasound to clinical research. Echocardiography is an operator-dependent technique 
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and variability of measurements may lead to collection of inaccurate data (133). 
Echocardiography is also dependent on image quality. 
In Study III, echocardiography was performed by two expert cardiologists as described in 
Section 4. The accuracy of the measurement of 2D/M-mode LV diameters is described as fair, 
and that of the measurement of EDT and E/e¢ as good (133). 
In Tromsø 6, the available echocardiographic measurements for the diagnosis of diastolic HF 
were the E/A ratio and EDT, LA diameter and TDI of the septal mitral annulus (and thereby 
calculation of the E/e¢ ratio). 
M-mode-derived LVEF has inherent limitations and is known to both over- and under-
estimate the severity of dysfunction; M-mode measurements do not necessarily reflect the true 
minor-axis dimension (134). However, because the majority of the participants were healthy 
individuals, the shortcomings of the method are of less importance. 
BMI 
In Study III, weight and height were measured by laboratory staff. BMI was calculated using 
a standardized method. Incorrect calibration of body weight measurement may cause 
systematic errors if the sensitivity and specificity vary between different ranges of the scale. 
Statistical power 
In Study III, the statistical significance level was set at 0.05 (5%). The sample size was 1,782 
participants. This large sample increased the statistical power and the chances of finding 
associations. However, the statistical power also depends on the prevalence of the outcome 
and the effect size. The prevalence of SpO2 £ 95% was higher in Study II than in Study III 
(22.0% and 6.4%, respectively). 
The participation rate in Tromsø 6 was 65.7%; a high participation rate is important for 
internal validity. In Study III, the participation rate was lower in the oldest age group, and this 
potential selection bias may have decreased the observed relationships between the findings. 
6.4.4 External validity 
In the Tromsø study, the invitation to participate came from the Norwegian Population 
Registry. Tromsø is the seventh largest Norwegian city, dominated by Caucasians of mainly 
Norwegian origin, and may be representative of a Northern European, white, urban 
population (135). The study is limited with regard to ethnic diversity (90). 
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6.4.5 Strengths of Study III 
The participation rate was high, which is important for the validity of the results. Previous 
adult population studies have not investigated the association between low oxygen saturation 
and DD. 
6.4.6 Limitations of Study III 
Cross-sectional data cannot establish causal relationships between pulse oximetry values and 
echocardiographic variables. 
In Study III, DD was classified by Doppler examinations of mitral inflow and of septal TDI at 
the mitral annulus, and LA size by M-mode diameter because only these variables were 
available. With some adjustments, we classified DD according to well-validated measures of 
DD that have been validated against mortality as an end-point (82). In their study, Redfield et 
al. (82) required participants to have two Doppler criteria consistent with DD to be so 
classified. Only one Doppler criterion was used in our definition of DD in Study III and this is 
a clear limitation. 
According to the 2016 recommendations for the evaluation of LV diastolic function by 
echocardiography, there are four recommended variables for identifying DD; if more than two 
of these do not meet the cut-off values for abnormal function, LV diastolic function is 
considered to be normal (83). 
In contrast with the previous guidelines, the 2016 classification has not yet been validated 
against mortality or hospitalization for heart failure as end-points. It is not possible to convert 
this study designed before 2016 to comply with the new guidelines because they incorporate 
variables rarely collected in population surveys. 
The echocardiographic data for DD were not connected to symptoms and we were unable to 
distinguish between participants with preclinical DD (PDD) and HF with HFpEF. N-terminal 
pro b-type natriuretic peptide was not measured in the Tromsø 6 study. 
PDD is prevalent and is defined as DD without a diagnosis of HF and with normal systolic 
function (136). Figure 10 shows the progression from preclinical DD to symptomatic HF 
including dyspnoea, oedema and fatigue. PDD is clinically significant, and it is essential to 
identify the risk factors for progression to HF and to delay progression to HFpEF using 
therapeutic intervention (136) .In our study, the participants with DD included those with both 
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The accuracy of SpO2 measurements could have been checked using arterial blood gas 





The study was presented to the Regional Committee for Medical and Health Research Ethics, 
South-East Norway, who judged this to be a clinical audit project, and therefore, not requiring 
formal approval by the committee. All patients provided signed informed consent allowing 
the analysis and publication of the results at an aggregated level that did not compromise 
patient anonymity. 
Study II 
Participating patients signed a written consent form and the study was approved by the 
Regional Committee for Medical and Health Research Ethics, North Norway. 
Study III 
The Regional Committee for Medical Research Ethics, North Norway approved the Tromsø 6 
survey. All the participants gave written informed consent and were able to withdraw their 
data from the study. Data were secured to maintain confidentiality, integrity and availability. 
An IT solution, the Tromsø Study database (EUTRO), was designed to protect and manage 
metadata, data and projects. Data security is in accordance with the requirements of the Data 













7. Clinical implications 
In recent years, technological advances have led to more point-of-care testing. This near-
patient testing has potential benefits for primary care. 
The GP is the first contact with the health care system for most patients with asthma and 
COPD in Norway. Primary care spirometry is a valuable tool in the evaluation of patients 
with respiratory symptoms (137). More accurate diagnosis of asthma and COPD patients is 
important and may lead to improved management, fewer symptoms and better quality of life 
(138). Spirometry data from the DIOLUP study showed that 64% of the patients with 
obstructive spirometry (FEV1/FVC < 0.7) had a diagnosis of COPD registered in their 
electronic medical record (87). This was an improvement in detection of COPD in routine 
care compared with previous studies (139, 140). In a study from Denmark, a diagnosis of 
COPD and subsequent treatment were supported by spirometric data in only 50% of cases 
(141). Under-use of spirometry is a major reason why COPD is underdiagnosed in primary 
care (142). Better implementation of spirometry testing in general practice is important. In a 
study from the U.K., women were more likely to have a GP diagnosis of COPD that was 
amended after spirometry (143). In recent years, the prevalence of COPD has been growing 
faster for women than for men in many countries (144), and this highlights the importance of 
spirometry in general practice. 
In the Lillestrøm study, primary care spirometry was useful for identifying ICS overuse. The 
limited use and implementation of spirometry do not necessarily correlate with a limited use 
of pulmonary medications. Other studies also indicate that ICS are overprescribed for COPD 
in general practice (145-147). In Denmark, improved prescribing of ICS according to the 
guidelines was achieved through education of the GPs and their staff (147). 
Spirometry needs to be more widely used to improve the accuracy of respiratory diagnoses in 
general practice (138). Early diagnosis is an issue, but it optimizes the opportunities to 
prevent worsening of disease and prevention of co-morbidities (142). 
Oxygen saturation measured by pulse oximetry is considered to be the “fifth vital sign” in 
addition to heart rate, temperature, blood pressure and respiratory rate (148). Pulse oximetry 
is now in common use in general practice and it is easy and safe to perform. The diagnostic 
benefits of pulse oximetry for diagnosis and treatment in general practice remain to be 
established. In the DIOLUP study, pulse oximetry seemed to be a useful measure in the 
follow-up of asthma and COPD patients, where decreased values may reflect suboptimal 
treatment and/or co-morbidity. Data from DIOLUP, not part of this PhD project, also show 
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that a severe decrease in SpO2 was a strong predictor of a drop in lung function during asthma 
and COPD exacerbations (8). It may be useful to take low pulse oximetry into account when 
considering treatment with oral corticosteroids (8). Low SpO2 was associated with increased 
all-cause mortality in a general adult population, probably because of a strong association 
with death caused by pulmonary disease and HF (10). SpO2 > 90% was an independent 
predictor of survival among lung cancer patients (149). This indicates that low pulse oximetry 
values may provide crucial clinical information in the follow-up of all patients with lung 
disease, including in general practice, but this should be confirmed in new studies. A 
diagnosis of CHD in the DIOLUP study and of DD in the Tromsø study was independently 
associated with decreased pulse oximetry values and these conditions should be included 
among possible explanations for low SpO2 values. In a Swedish register-based study, primary 
care was the only care provider to 21% of patients with coexisting HF and COPD (150). To 
understand the clinical consequences of this co-morbidity (18), greater collaboration is 
required between cardiologists, pulmonologists and GPs caring for such patients (18). 
Driver’s licence regulations prepared by the Norwegian Directorate of Health (151) advise the 
GP to refer to specialist assessment if patients have SpO2 < 90% or FEV1% predicted < 30%. 
This exemplifies that it is important for GPs to have experience in measuring and interpreting 















8. Conclusion and future perspectives 
Through our three studies, we have according to the detailed aims: 
1. Gained knowledge about the use of spirometry and pulse oximetry in general practice for 
patients with lung and/or heart diseases. A clinical audit including spirometry was useful 
for identifying overuse of ICS.  
2. Pulse oximetry was shown to be a valid measure in the follow-up for asthma and COPD 
patients in general practice; it is also important to look for co-morbidities, including a 
diagnosis of CHD.  
3. DD should be included among possible explanations when decreased oxygen saturation is 
found. 
 
8.1 What is a good diagnostic test for a GP? 
There is no easy answer to this question; the answer lies not only in the sensitivity and 
specificity of the diagnostic tests, but it has also to do with the GP’s skills in using these tests 
in clinical practice. It is important that more research be conducted in general practice to 
confirm these associations and to determine the best cut-off points for SpO2 and the 
implementation of spirometry. We are in the process of establishing a research network in 
general practice in Norway that may be viewed as a laboratory for primary care research 
(152). This will make it easier to include patients from representative medical centres and 
regions in Norway and hence achieve better external validity for future studies. Other fields of 
interest for testing pulse oximetry values in general practice are patients having acute 
consultations because of breathing problems and/or chest pain, children with signs of 
pneumonia, and for follow-up of patients with HF. With more knowledge available, we could 
ask: “How are low pulse oximetry values useful in decision-making about the treatment of 
patients in general practice, for example, for patients with COPD, asthma, HF or pneumonia? 
Which SpO2 values does the GP act on in different settings?” A new diagnosis of obstructive 
lung disease was associated with increased rates of smoking cessation in COPD patients 
(153); the new diagnosis of COPD gave the participants motivation to stop smoking (153). 
This indicates that spirometry is a useful diagnostic test for all smokers. We also need more 
research about the association between pulse oximetry and HF (both systolic and diastolic) 
from patients followed up in primary care. 
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In the fast-moving context of telehealth care, spirometry and pulse oximetry are tests that fit 
well for implementation in telemonitoring in primary care. In 2008 in Greenland, a computer-
based telemedicine system called “Pipaluk” was implemented to provide citizens living in 
rural areas with easier access to health care. The computer-based system was connected to 
various medical devices, including for oxygen saturation and spirometry, and to an 
examination camera (61). Greenlandic citizens regard telemedicine as a facilitator of 
improved access to health care in the Greenlandic Settlements (61). 
There are no reliable data to support or refute patient use of pulse oximeters to monitor 
oxygen saturation levels when experiencing an asthma attack (154). Some patients have a 
reduced perception of the severity of their own breathlessness when exposed to hypoxia 
(154). Pulse oximetry might be beneficial for those who have such a lowered perception of 
their hypoxia, but this has not been studied in patients having an asthma attack (154). Pulse 
oximetry used incorrectly in this setting could delay the patient seeking appropriate medical 
help and worsen outcomes. Pulse oximetry needs to be interpreted in the context of the whole 
clinical scenario, not in isolation (155). 
A low-cost phone oximeter is now available; this might be important in low- and middle-
income countries because these areas of the world remain largely without access to advanced 
health technology, while phones are widely available (156). The quality of these 
measurements needs to be assessed. We also need more evidence from general practice about 
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